Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My guess is they won't. They will remain argumentative and contrary about anything related to Amarin. I posted a year ago and it is still true today....Amarin (with Vascepa) is an existential threat to the FDA! They won't "go gentle into that good night". They will rage on and on until forced to end their vendetta.
Stay optimistic but..........don't hold your breath. The FDA is staffed by the most arrogant collection of human beings of any on this earth.
Don't have "private message" access Bio, but would love to read, (drrc1949@aol.com)
(Multiple thumbs).
In addition to jamming the hammer down on illegal naked shorting, the SEC really does need to reinstate the uptick rule on short sales. I'm not totally pro or totally con President Obama, but with this kind of BS going on right in front of our eyes, why the f__k is he warning John Q about the possibility of biased "financial advisors"? That is the LEAST of our problems!
It really is appalling how the HFs and MMs manipulate the stock of this little company! More than 1,200,000 shares right at the close down as low as $1.34 before recovering to $1.46. Guess it's all legal though......right?
Gotta admit it Zu, you are "on fire"!!
WRT my UHC/CVS Vascepa coverage, I could manage to push my TGs up too but wouldn't matter.....they completely removed V from coverage.....period!
That is certainly under consideration, although his particular area of specialization is crucial to me. Nevertheless, if he fails to back me with my insurer on V, I will exit his care.
To make a long story short, I was covered by the same medical plans for all of 2014 as I am covered by now in 2015 - Medicare Primary, UHC Secondary. For 2014, my 90-day Vascepa prescription with Amarin Coupon required a copay amount of $137.14. In November of 2014, I was notified by CVS that Vascepa would no longer be covered under my benefit plan. My first 90-day Vascepa renewal in 2015 with Amarin Coupon was quoted to me at approx $607.00 but a 30-day supply was quoted at $157.14 (can't say I'm real clear on this math) so I opted for one month at a time.
I called Amarin for any assistance they could provide in encouraging my Cardio to pre-authorize but all they could offer was the Discount Coupon Program. So far my Cardio has replied that I must use Lovaza (fat fucking chance of that) so I am applying more pressure on him. Outcome is indeterminate at this time except that Vascepa is no longer included on the CVS formulary within my United Healthcare plan.
Thank you Kiwi, I recalled that you had spoken of this in the past but I couldn't find the references. I appreciate your help and advice!
Thanks dude, that's what I was looking for. I remember OmegaVia now that you mention it.....others have recommended in the past. I've been fortunate 'til now in being prescribed V with insurance coverage. That ended on Jan 1 with new UHC/CVS formulary so now I'm also scrambling to get my physician to pre-auth. We'll see....thanks again!
I have a friend who hasn't yet been able to get a prescription for V. She wants to take an EPA supplement perhaps with a low dose of DHA. Anyone have the latest on untainted dietary supplements re: purity, price, vendor?
Hey hey BC, that is wonderful news! God Bless you and your family, most especially the newest addition. Wishing you all health and happiness today and all the days to come.......Drrc
1bill, I don't know about you but I have a whole new appreciation for and understanding of the phrase "pompous asshole".
Post it.....Absolutely!
BioBill, what??....you question the integrity of a physician affiliated with Harvard Medical School? Better watch your step or you'll get yourself scolded by Kiwi! For my own part, any day of the week I'll take integrity, honest criticism and a little independent thinking over the Harvard Medical School profile! Just because you talk it doesn't always mean you walk it.
IITF, this is an excellent piece of DD, thanks for your continued efforts. I admit I'd appreciate a little fanfare on this from Titan but I'll take consolation from the knowledge that I'm invested in a winner. When an engineer is truly impressed with the solution to a difficult problem, I've heard a word used that can easily apply to this patent........elegant!
Here's an interesting take on the Jupiter Trial that evaluated Crestor. Anyone surprised?
archinte.jamanetwork.com/article.aspx?articleid=416101
Conclusion The results of the trial do not support the use of statin treatment for primary prevention of cardiovascular diseases and raise troubling questions concerning the role of commercial sponsors.
Results The trial was flawed. It was discontinued (according to prespecified rules) after fewer than 2 years of follow-up, with no differences between the 2 groups on the most objective criteria. Clinical data showed a major discrepancy between significant reduction of nonfatal stroke and myocardial infarction but no effect on mortality from stroke and myocardial infarction. Cardiovascular mortality was surprisingly low compared with total mortality—between 5% and 18%—whereas the expected rate would have been close to 40%. Finally, there was a very low case-fatality rate of myocardial infarction, far from the expected number of close to 50%. The possibility that bias entered the trial is particularly concerning because of the strong commercial interest in the study.
Perhaps the lack of any chatter from Columbia is indicative of their satisfaction with events as they are playing out? As has been posted previously, the dichotomy of opinions on this board really may be attributed to different mindsets held by medical professionals versus non-medical investors.
When you look at Titan's price action and volume during December, it seems apparent that any tax seling took place early in the month culminating around the 17th when a brief sympathy rally with TRXC buoyed it back up. From there it's just been drifting down on lower volume into month end. If there is anything to the idea of a "January Effect", I'd say we might be in for a little ride!
kingsransome, you are full of sh|t! But I love your enthusiastic posts, I smile every time I see one! One day you'll be right.....I hope! Happy Holidays!
It doesn't.....just take the Vascepa. Oh, and don't watch Fox News....you'll be healthier and live longer! JMO, happy holidays to you!
I'd like to personally thank LTG for nosing around this board...if it wasn't for you I probably wouldn't have been aware of the action on TRXC yesterday. After you pointed it out, I looked it over and decided to take a small gamble. I tried to buy 50 Calls @ a nickel but only got 20 executed. A short while ago, I sold those 20 Calls for $1.50 and used the proceeds to buy another 1500 shares of TITXF! That leaves me enough for a big bottle of Johnnie Walker Black and another of Crown Royal. Thank you Canada and Merry Christmas LTG! Ho-freakin'-ho and GLTA.
It's a game changer for the FDA to officially recognize the causative role chronic inflammation plays in the development of CHD. But there are many on this board who now have heightened concerns because we (Amarin) are still SELLING Triglyceride pills! Some believe we should stay the course and not rock the FDA boat, just keep selling and wait for Reduce-It. It looks to me that if Amarin doesn't get the real Vascepa message out there soon, then our competition will do it for us! AZN, GSK, MRK...they'll have no qualms over sinking FDAs boat and they won't be sitting around "waiting for Reduce-It"! They'll get their own products to market that "reduce inflammation" and in the process they'll either bury Vascepa or steal it from the corpse of Amarin. Right now, Amarin should be doing what's best for Amarin (and us), and that means anything it takes to stay alive! Sadly though, this company acts like it has a death wish. Not much else to say.....RIP.
If forced to take a side, I'd be compelled to vote YAY on that issue due to the historically sterling reputation of the United States Food and Drug Administration.
With all due respect, Zip, your last post sounds like something out of Mary Poppins. Neither you nor I should be trusting management on anything! I'm not saying they've done a lot of things wrong but they haven't shown me that they've done a lot of things right either. All of us need to keep pressing them for action because they have too great a tendency to sit around and wait for things to happen. It's time that they got very proactive...push the goddamn envelope on 1st Amendment rights and start up the PR engine! Biobill is right on the MONEY!
I'm in the same situation as you North, CVS plans on switching me to Lovaza from Vascepa. I already did Lovaza for a year and some back in 2010 but I couldn't take it any longer....burps, upset stomach, taste problems. I'm going into battle as well, good luck to you!
You're right AltP, I can't read it, it turns my stomach faster than Lovaza ever did. I want to say more but reading his lies about how successful they've been and how poorly paid they all are truly makes me sick. Go to hell Jenkins and take the rest of your lying cohorts with you.
Obviously, FF, that would be the next rational assumption. Why hasn't the FDA taken any action to help insure that Amarin survives through the end of the Reduce-It study? And now there is so much new positive information about the effects of EPA....
What are we really expecting to hear on January 16, HD?
I have purchased stock but I've also purchased options. In fact, worthless expired options have resulted in the bulk of my "real" losses on Amarin. I currently control 40,000 shares thru 400 Jan 15, 2016 Calls and more than 100,000 additional shares thru well over 1,000 2015 Calls expiring in various months of 2015. I am currently focusing on recently issued Jan 20, 2017 Calls. I will use a strategy of selling stock and options when and if the time is ever right. I will roll some proceeds forward into future OTM Calls to recoup prior losses and perhaps, maybe one day see a profit.
I submitted the following (red and blue) to Amarin Investor Relations earlier today.
To: Investor Relations
Subject: Vascepa Insurance Coverage
The following comment was submitted to the Amarin Corporation plc website by drrc1949:
"The company has stated: "We've secured 95% of the existing Tier 2 coverage to 2015 and additional renewals are scheduled to review soon." There is confusion over the phrase "to 2015"...does the statement mean that as of today (12/01/2014), 95% of existing Tier 2 Coverage has been extended/renewed through the end of 2015?
Investor Relations responded: "Good afternoon. Yes that is correct."
Recently my experience has been that not only are insurers offering Tier 2 Coverage less frequently, they aren't even continuing coverage at any Tier! However, Amarin has stated clearly that they have successfully retained 95% of existing Tier 2 coverage through the end of 2015. I'll need to accept that for now and see how things evolve.
louie - Total, complete and absolute Bullshit!
Zu, there are three entities that give a shit about this study.....you, me and the study sponsors. Nobody else gives a flying fuck!
I'd be willing to bet you $500.00 that the comments published were all written professionally. Have you read the comments on this and other boards, just make a comparison and you'll agree.
JL, nice, very clear, very clean, slick metaphors......you have been working!
STS,
"Is that even legal?"
Abso-freakin'-lutely! It's determined by the Providers, the Insurance Companies.
Ooops..............!
HD, you are a marvel. Thank you!
OK, so you have the drug with the recognized name - Lovaza - being sold for less than half the price of the newcomer - Vascepa. Because the FDA reneged on the Amarin SPA, each drug is approved for the same indication. As far as Prescription Management Providers are concerned, cheaper is better! So Lovaza wins and Vascepa goes off coverage.
I am not a basher and I hope this is not where we are headed but a year of no or limited coverage for Vascepa could be the final nail in the coffin. It seriously concerns me.
Somebody within the last week or two posted something about "bargain basement" pricing of Lovaza. I mean't to follow up at the time but got distracted, but I wondered if this was really factual and not just speculation! Anyone else recall the post?